{'52WeekChange': 0.27617323,
 'SandP52WeekChange': 0.0644362,
 'address1': '60 Leveroni Court',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 77.75,
 'askSize': 1300,
 'averageDailyVolume10Day': 377887,
 'averageVolume': 529376,
 'averageVolume10days': 377887,
 'beta': 2.267226,
 'beta3Year': None,
 'bid': 77.7,
 'bidSize': 1200,
 'bookValue': 10.24,
 'category': None,
 'circulatingSupply': None,
 'city': 'Novato',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 78.52,
 'dayLow': 76.14,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -9.226,
 'enterpriseToRevenue': 33.039,
 'enterpriseValue': 4025861376,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '415 483 8810',
 'fiftyDayAverage': 78.81371,
 'fiftyTwoWeekHigh': 91.77,
 'fiftyTwoWeekLow': 31.99,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 56337510,
 'forwardEps': -4.95,
 'forwardPE': -15.711111,
 'fromCurrency': None,
 'fullTimeEmployees': 740,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.06138,
 'heldPercentInstitutions': 1.01472,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': 1389916800,
 'lastSplitFactor': '1:3',
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/ultragenyx.com',
 'longBusinessSummary': 'Ultragenyx Pharmaceutical Inc., a biopharmaceutical '
                        'company, focuses on the identification, acquisition, '
                        'development, and commercialization of novel products '
                        'for the treatment of rare and ultra-rare genetic '
                        'diseases in the United States. Its biologic products '
                        'include Crysvita (burosumab), an antibody targeting '
                        'fibroblast growth factor 23 for the treatment of '
                        'X-linked hypophosphatemia; and Mepsevii, an enzyme '
                        'replacement therapy for the treatment of children and '
                        'adults with Mucopolysaccharidosis VII. The company is '
                        'also developing small-molecule pipeline comprising '
                        'UX007, a synthetic triglyceride for the treatment of '
                        'long chain fatty-acid oxidation disorders, which is a '
                        'set of rare metabolic diseases that prevents the '
                        'conversion of fat into energy; and gene therapy '
                        'pipeline consisting of DTX301, an adeno-associated '
                        'virus 8 gene therapy product candidate for the '
                        'treatment of patients with ornithine '
                        'transcarbamylase, as well as DTX401, an AAV8 gene '
                        'therapy clinical candidate for the treatment of '
                        'patients with glycogen storage disease type Ia. In '
                        'addition, the company is developing UX068, which is '
                        'in preclinical development for the treatment of '
                        'creatine transporter deficiency (CTD); and UX053 for '
                        'the treatment of glycogen storage disease type III. '
                        'Ultragenyx Pharmaceutical Inc. has collaboration and '
                        'license agreement with Arcturus Therapeutics Holdings '
                        'Inc. to develop additional nucleic acid therapies for '
                        'rare diseases. Ultragenyx Pharmaceutical Inc. was '
                        'founded in 2010 and is headquartered in Novato, '
                        'California.',
 'longName': 'Ultragenyx Pharmaceutical Inc.',
 'market': 'us_market',
 'marketCap': 4646694912,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_117471985',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -424996000,
 'nextFiscalYearEnd': 1640908800,
 'open': 78.01,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': -0.72,
 'phone': '415 483 8800',
 'previousClose': 78.93,
 'priceHint': 2,
 'priceToBook': 7.5947266,
 'priceToSalesTrailing12Months': 38.134235,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 78.52,
 'regularMarketDayLow': 76.14,
 'regularMarketOpen': 78.01,
 'regularMarketPreviousClose': 78.93,
 'regularMarketPrice': 78.01,
 'regularMarketVolume': 377239,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 59749200,
 'sharesPercentSharesOut': 0.1284,
 'sharesShort': 7670727,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 7594644,
 'shortName': 'Ultragenyx Pharmaceutical Inc.',
 'shortPercentOfFloat': 0.1774,
 'shortRatio': 13.58,
 'startDate': None,
 'state': 'CA',
 'strikePrice': None,
 'symbol': 'RARE',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -7.356,
 'twoHundredDayAverage': 62.609962,
 'volume': 377239,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.ultragenyx.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '94949'}